Stroke/Vascular Neurology News

CHICAGO — In the BRAIN-AF trial, daily rivaroxaban did not reduce the incidence of cognitive decline, stroke or transient ischemic attack, compared with placebo, among younger patients with atrial fibrillation and low stroke risk.

Cardiovascular health of middle-aged adults was significantly associated with the risk of poor brain health later in life, according to a study published in Neurology.

October 29 is World Stroke Day, which aims to raise awareness of the condition and how to prevent it.

Oral semaglutide demonstrated an approximately 14% reduction in major adverse CV events compared with standard care along in patients with diabetes, CVD and/or kidney disease, according to the top-line results of the phase 3 SOUL trial.

The new guideline on primary prevention of stroke from the American Heart Association and American Stroke Association calls for more screening of risk factors such as high BP, high cholesterol and high blood glucose.

Nearly 5% of older adults initiate benzodiazepine after discharge for acute ischemic stroke, half of which receive up to a 30-day supply, despite known risks for cognitive decline, researchers reported in Stroke.

The FDA has granted premarket approval to the Neuroguard IEP System, a novel stenting system intended to ease the process for individuals with stroke, according to the manufacturer.

Noninvasive speckle contrast optical spectroscopy may be a feasible method for determining whether individuals are at high or low risk for stroke, according to a study published in Biomedical Optics Express.

Exposure to air pollution was linked to higher ischemic stroke incidence among women younger than 65 years and residents of areas with high alcohol and tobacco consumption, researchers reported in European Journal of Preventive Cardiology.